02:19 PM EDT, 08/14/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) plans to advance two advanced RNAi-based drug candidates, ARO-INHBE and ARO-ALK7, for clinical studies to target obesity and metabolic disorders.

In preclinical tests, the drug candidates showed potential for reducing body weight and fat while preserving lean muscle mass better than existing therapies, Arrowhead said Wednesday

The company plans to submit clinical trial applications for both programs by late 2024 and start studies in early 2025.

Price: 22.52, Change: -0.33, Percent Change: -1.47